These findings provide a potential mechanism through which TIM3 is highly expressed and activated in macrophages and causes HSC activation and NASH fibrosis, highlighting a possible therapeutic strategy for the treatment of fibrosis in chronic NASH patients. Here, HAVCR2 is linked to metabolic dysfunction-associated steatohepatitis.